🟢 Gossamer Bio is trading 11.52% up in pre-market after Chardan initiates coverage with a Buy rating

Gossamer Bio is trading 11.52% higher in pre-market at $10.35 after Chardan initiated coverage with a Buy rating and a $160 price target, citing seralutinib’s potential despite the Phase 3 PROSERA trial’s narrow statistical miss.

• Chardan published its note at 3:52 a.m. ET on October 13, before the alert; the report does not independently confirm it caused the move.
• The company announced its FDA application for seralutinib in September, not October 13. Shares closed at $9.28 on October 12; no reliable pre-market volume figure is available.